Santiago-Sánchez GS, Noriega-Rivera R, Hernández-O'Farrill E, Valiyeva F, Quiñones-Diaz B, Villodre ES, Debeb BG, Rosado-Albacarys A, Vivas-Mejía PE. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int J Mol Sci 2021;22:8581. [PMID: 34445288 DOI: 10.3390/ijms22168581][Cited by in Crossref: 3][Cited by in F6Publishing: 3][Article Influence: 1.5][Reference Citation Analysis]
Number
Citing Articles
1
Kuo C, Hsieh P, Chiu V, Lan C, Lu K. The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways. Oxidative Medicine and Cellular Longevity 2023;2023:1-15. [DOI: 10.1155/2023/7736638][Reference Citation Analysis]
2
Mchenry PR, Prosperi JR. Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential. IJMS 2023;24:2100. [DOI: 10.3390/ijms24032100][Reference Citation Analysis]
Valashedi MR, Roushandeh AM, Tomita K, Kuwahara Y, Pourmohammadi-Bejarpasi Z, Kozani PS, Sato T, Roudkenar MH. CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability. Life Sci 2022;304:120704. [PMID: 35714703 DOI: 10.1016/j.lfs.2022.120704][Cited by in Crossref: 3][Cited by in F6Publishing: 3][Article Influence: 3.0][Reference Citation Analysis]
